News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors
globaloncologyacademy.org
Nov 11, 2024, 23:44

Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors

Niklas Klümper, Senior Consultant for Urology and GU Oncology at University Hospital Bonn, shared a post on X:

“New data shows T-DXd achieving high ORR with durable response in patients with advanced HER2-amplified solid tumors, as determined by cfDNA testing!

A strong example of an elegant biomarker-based basket design, further supporting tumor-agnostic approval of T-DXd for HER2-positive cancers.”

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

Authors: Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Odegaard, Satoshi Fujii, Shogo Nomura, Hideaki Bando, Akihiro Sato, Takayuki Yoshino, Yoshiaki Nakamura

Niklas Klümper

Akihiro Sato Ayako Doi cancer cfDNA testing Daisuke Sakai HER2-positive cancers Hideaki Bando Hiromi Ono Hiroya Taniguchi Justin Odegaard Masataka Yagisawa Masatoshi Asano Nami Hirano Niklas Klümper OncoDaily Oncology Satoshi Fujii Shigenori Kadowaki Shogo Nomura solid tumors Taito Esaki Takayuki Yoshino Takeshi Kajiwara Taroh Satoh Tomohiro Nishina Trastuzumab deruxtecan Yoshiaki Nakamura Yoshito Komatsu Yu Sunakawa
Special Coverage
Celebrities
Jan 16, 2025, 17:18
Bob Uecker Dies at 90 from Small-Cell Lung Cancer
Insight
Jan 16, 2025, 16:45
The 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents
Insight
Jan 16, 2025, 16:28
ACS CAN Report: High Costs Block Critical Follow-Up Tests for Breast Cancer
Blog
Jan 16, 2025, 16:20
Genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC - ASGO Education
Science
Jan 16, 2025, 16:10
Neoadjuvant therapy in patients with left-sided resectable pancreatic cancer
Blog
Jan 16, 2025, 16:05
David Wakeling: Alice’s Arc’s new research grant to some of the best minds in US paediatric cancer research
Science
Jan 16, 2025, 16:03
Estela Rodriguez: Updated analysis of CM816
Blog
Jan 16, 2025, 16:01
Elizabeth Ugwoma Awo-Ejeh: The Power of Showing Up - Closing the 10-Day Challenge
Career
Jan 16, 2025, 15:57
Elene Mariamidze: I finally got into the 2025 IASLC Academy
Insight
Jan 16, 2025, 15:50
The Gynaecology Course at the 17th BGICC
Insight
Jan 16, 2025, 15:49
Elvina Almuradova: Delighted to continue serving as a ESO Ambassador for Turkey
Blog
Jan 16, 2025, 15:46
Roupen Odabashian: Why do I see more young patients with cancer?